Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Teva settle UK Lipitor patent case

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor in the UK

Pfizer has settled its case against Teva regarding the launch of a generic version of cholesterol lowering medication Lipitor (atorvastatin) in the UK.

Under the terms of the agreement Teva and the other settling parties have agreed not to sell the generic atorvastatin product in the UK before patent expiry in May 2012.

Teva said it acknowledged that Pfizer's Lipitor patent was valid and its product infringed Pfizer's rights.

Pfizer extended the drug's patent protection by six months to May 2012 in Europe, with the announcement of new paediatric data enabling the launch of a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

However, generic versions of the drug are already available in certain countries including Spain, Brazil and Mexico, with Lipitor's second quarter sales down from $2.81bn in 2010 to $2.59bn in 2011.

10th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics